Prognostic value of 18F-fluorodeoxyglucose positron emission tomography in patients with extrahepatic bile duct cancer

详细信息    查看全文

• 作者：Koji Kitamura (1)
  Etsuro Hatano (1)
  Tatsuya Higashi (3)
  Satoru Seo (4)
  Yuji Nakamoto (2)
  Masato Narita (1)
  Kojiro Taura (1)
  Kentaro Yasuchika (1)
  Takashi Nitta (1)
  Kenya Yamanaka (1)
  Ryuichiro Doi (1)
  Iwao Ikai (1)
  Shinji Uemoto (1)
  
• 关键词：Fluorine ; 18 fluorodeoxyglucose positron emission tomography ; Extrahepatic bile duct cancer ; Standardized uptake value ; Lymph node metastasis ; Prognostic factor
• 刊名：Journal of Hepato-Biliary-Pancreatic Sciences
• 出版年：2011
• 出版时间：January 2011
• 年：2011
• 卷：18
• 期：1
• 页码：39-46
• 全文大小：216KB
• 参考文献：1. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet. 2005;366(9493):1303-4. CrossRef
  2. Lazaridis KN, Gores GJ. Cholangiocarcinoma. Gastroenterology. 2005;128(6):1655-7. CrossRef
  3. Yee K, Sheppard BC, Domreis J, Blanke CD. Cancers of the gallbladder and biliary ducts. Oncology (Williston Park). 2002;16(7):939-6, 949 (discussion 949-0, 952-, 956-).
  4. Daines WP, Rajagopalan V, Grossbard ML, Kozuch P. Gallbladder and biliary tract carcinoma: a comprehensive update, part 2. Oncology (Williston Park). 2004;18(8):1049-9. (discussion 1060, 1065-, 1068).
  5. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med. 1999;341(18):1368-8. CrossRef
  6. Henson DE, Albores-Saavedra J, Corle D. Carcinoma of the extrahepatic bile ducts. Histologic types, stage of disease, grade, and survival rates. Cancer. 1992;70(6):1498-01. CrossRef
  7. Delbeke D, Martin WH. Positron emission tomography imaging in oncology. Radiol Clin North Am. 2001;39(5):883-17. CrossRef
  8. Hustinx R, Benard F, Alavi A. Whole-body FDG-PET imaging in the management of patients with cancer. Semin Nucl Med. 2002;32(1):35-6. CrossRef
  9. Kluge R, Schmidt F, Caca K, Barthel H, Hesse S, Georgi P, et al. Positron emission tomography with [(18)F]fluoro-2-deoxy-d -glucose for diagnosis and staging of bile duct cancer. Hepatology. 2001;33(5):1029-5. CrossRef
  10. Keiding S, Hansen SB, Rasmussen HH, Gee A, Kruse A, Roelsgaard K, et al. Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography. Hepatology. 1998;28(3):700-. CrossRef
  11. Widjaja A, Mix H, Wagner S, Graz KF, van den Hoff J, Petrich T, et al. Positron emission tomography and cholangiocarcinoma in primary sclerosing cholangitis. Z Gastroenterol. 1999;37(8):731-.
  12. Moon CM, Bang S, Chung JB, Park SW, Song SY, Yun M, et al. Usefulness of 18F-fluorodeoxyglucose positron emission tomography in differential diagnosis and staging of cholangiocarcinomas. J Gastroenterol Hepatol. 2008;23(5):759-5. CrossRef
  13. Corvera CU, Blumgart LH, Akhurst T, DeMatteo RP, D’Angelica M, Fong Y, et al. 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J Am Coll Surg. 2008;206(1):57-5. CrossRef
  14. Kato T, Tsukamoto E, Kuge Y, Katoh C, Nambu T, Nobuta A, et al. Clinical role of (18)F-FDG PET for initial staging of patients with extrahepatic bile duct cancer. Eur J Nucl Med Mol Imaging. 2002;29(8):1047-4. CrossRef
  15. Anderson CD, Rice MH, Pinson CW, Chapman WC, Chari RS, Delbeke D. Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg. 2004;8(1):90-. CrossRef
  16. Lyshchik A, Higashi T, Nakamoto Y, Fujimoto K, Doi R, Imamura M, et al. Dual-phase 18F-fluoro-2-deoxy-d -glucose positron emission tomography as a prognostic parameter in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging. 2005;32(4):389-7. CrossRef
  17. Hatano E, Ikai I, Higashi T, Teramukai S, Torizuka T, Saga T, et al. Preoperative positron emission tomography with fluorine-18-fluorodeoxyglucose is predictive of prognosis in patients with hepatocellular carcinoma after resection. World J Surg. 2006;30(9):1736-1. CrossRef
  18. Hasegawa S, Ikai I, Fujii H, Hatano E, Shimahara Y. Surgical resection of hilar cholangiocarcinoma: analysis of survival and postoperative complications. World J Surg. 2007;31(6):1256-3. CrossRef
  19. Japanese Society of Biliary Surgery. Classification of biliary tract carcinoma, 2nd English edn. Tokyo: Kanehara; 2004.
  20. Sobin LH. TNM, sixth edition: new developments in general concepts and rules. Semin Surg Oncol. 2003;21(1):19-2. CrossRef
  21. Higashi T, Tamaki N, Honda T, Torizuka T, Kimura T, Inokuma T, et al. Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. J Nucl Med. 1997;38(9):1337-4.
  22. Seo S, Hatano E, Higashi T, Nakajima A, Nakamoto Y, Tada M, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts lymph node metastasis, P-glycoprotein expression, and recurrence after resection in mass-forming intrahepatic cholangiocarcinoma. Surgery. 2008;143(6):769-7. CrossRef
  23. Furukawa H, Ikuma H, Asakura K, Uesaka K. Prognostic importance of standardized uptake value on F-18 fluorodeoxyglucose-positron emission tomography in biliary tract carcinoma. J Surg Oncol. 2009;100(6):494-. CrossRef
  24. Fritscher-Ravens A, Bohuslavizki KH, Broering DC, Jenicke L, Schafer H, Buchert R, et al. FDG PET in the diagnosis of hilar cholangiocarcinoma. Nucl Med Commun. 2001;22(12):1277-5. CrossRef
  25. Buck A, Schirrmeister H, Kuhn T, Shen C, Kalker T, Kotzerke J, et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging. 2002;29(10):1317-3. CrossRef
  26. Halfpenny W, Hain SF, Biassoni L, Maisey MN, Sherman JA, McGurk M. FDG-PET. A possible prognostic factor in head and neck cancer. Br J Cancer. 2002;86(4):512-. CrossRef
  27. Dhital K, Saunders CA, Seed PT, O’Doherty MJ, Dussek J. [(18)F]Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer. Eur J Cardiothorac Surg. 2000;18(4):425-. CrossRef
  28. Blake MA, Singh A, Setty BN, Slattery J, Kalra M, Maher MM, et al. Pearls and pitfalls in interpretation of abdominal and pelvic PET-CT. Radiographics. 2006;26(5):1335-3. CrossRef
  29. Kim JY, Kim MH, Lee TY, Hwang CY, Kim JS, Yun SC, et al. Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging. Am J Gastroenterol. 2008;103(5):1145-1. CrossRef
  30. Wakabayashi H, Akamoto S, Yachida S, Okano K, Izuishi K, Nishiyama Y, et al. Significance of fluorodeoxyglucose PET imaging in the diagnosis of malignancies in patients with biliary stricture. Eur J Surg Oncol. 2005;31(10):1175-. CrossRef
  31. Kiba T, Nishimura T, Matsumoto S, Hatano E, Mori A, Yasumi S, et al. Single-agent gemcitabine for biliary tract cancers. Study outcomes and systematic review of the literature. Oncology. 2006;70(5):358-5. CrossRef
  32. Sakamoto E, Nimura Y, Hayakawa N, Kamiya J, Kondo S, Nagino M, et al. The pattern of infiltration at the proximal border of hilar bile duct carcinoma: a histologic analysis of 62 resected cases. Ann Surg. 1998;227(3):405-1. CrossRef
  33. Jarnagin WR, Bowne W, Klimstra DS, Ben-Porat L, Roggin K, Cymes K, et al. Papillary phenotype confers improved survival after resection of hilar cholangiocarcinoma. Ann Surg. 2005;241(5):703-2. (discussion 12-). CrossRef
  34. Isaji S, Kawarada Y, Taoka H, Tabata M, Suzuki H, Yokoi H. Clinicopathological features and outcome of hepatic resection for intrahepatic cholangiocarcinoma in Japan. J Hepatobiliary Pancreat Surg. 1999;6(2):108-6. CrossRef
  35. Kitagawa Y, Nagino M, Kamiya J, Uesaka K, Sano T, Yamamoto H, et al. Lymph node metastasis from hilar cholangiocarcinoma: audit of 110 patients who underwent regional and paraaortic node dissection. Ann Surg. 2001;233(3):385-2. CrossRef
  36. Kondo S, Takada T, Miyazaki M, Miyakawa S, Tsukada K, Nagino M, et al. Guidelines for the management of biliary tract and ampullary carcinomas: surgical treatment. J Hepatobiliary Pancreat Surg. 2008;15(1):41-4. CrossRef
  37. Nakamoto Y, Chang AE, Zasadny KR, Wahl RL. Comparison of attenuation-corrected and non-corrected FDG-PET images for axillary nodal staging in newly diagnosed breast cancer. Mol Imaging Biol. 2002;4(2):161-. CrossRef
  38. Ebata T, Watanabe H, Ajioka Y, Oda K, Nimura Y. Pathological appraisal of lines of resection for bile duct carcinoma. Br J Surg. 2002;89(10):1260-. CrossRef
  39. Kondo S, Hirano S, Ambo Y, Tanaka E, Okushiba S, Morikawa T, et al. Forty consecutive resections of hilar cholangiocarcinoma with no postoperative mortality and no positive ductal margins: results of a prospective study. Ann Surg. 2004;240(1):95-01. CrossRef
  40. Wakai T, Shirai Y, Moroda T, Yokoyama N, Hatakeyama K. Impact of ductal resection margin status on long-term survival in patients undergoing resection for extrahepatic cholangiocarcinoma. Cancer. 2005;103(6):1210-. CrossRef
  
• 作者单位：Koji Kitamura (1)
  Etsuro Hatano (1)
  Tatsuya Higashi (3)
  Satoru Seo (4)
  Yuji Nakamoto (2)
  Masato Narita (1)
  Kojiro Taura (1)
  Kentaro Yasuchika (1)
  Takashi Nitta (1)
  Kenya Yamanaka (1)
  Ryuichiro Doi (1)
  Iwao Ikai (1)
  Shinji Uemoto (1)
  
  1. Department of Surgery, Graduate School of Medicine Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan
  3. Shiga Medical Center Research Institute, 5-4-30 Moriyama, Moriyama, Shiga, 524-8524, Japan
  4. Department of Digestive Surgery, Mitsubishi Kyoto Hospital, 1 Katsuragosho-cho, Nishikyo-ku, Kyoto, 615-8087, Japan
  2. Department of Diagnostic Imaging and Nuclear Medicine, Graduate School of Medicine Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan
  

文摘

Background 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) is used in the differential diagnosis and staging of extrahepatic bile duct cancer (EBDC), but its prognostic value has not been fully elucidated. In this study, we investigated the prognostic value of FDG-PET in EBDC patients. Methods The study included 73 consecutive patients with EBDC, of whom 48 underwent surgical resection for EBDC. The effects of clinicopathological factors including the standardized uptake value (SUV) of the primary lesion and lymph node metastasis detected by FDG-PET (PET-N) on overall survival were evaluated. Results In all 73 patients, multivariate analysis showed that surgical resection (risk ratio 2.5, 95% confidence interval [CI] 1.17-.35, P?=?0.018) and the SUV (2.0, 1.07-.91, P?=?0.030) were independent predictors of survival. In the 48 patients who underwent surgical resection, multivariate analysis revealed that perineural invasion (risk ratio 3.2, 95% CI 1.28-.93, P?=?0.012), pathologic lymph node metastasis (3.4, 1.27-.17, P?=?0.015), and PET-N (4.0, 1.10-5.25, P?=?0.036) were independent predictors of overall survival. In the 25 patients without surgical resection, the SUV showed a significant relationship with overall survival (P?=?0.014). Conclusion Our data suggest that the SUV of the primary lesion is a useful prognostic factor in patients with EBDC, and the prognosis for patients with PET-N remains very poor despite surgical resection.